78 related articles for article (PubMed ID: 27089226)
1. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
Kawano Y; Takahashi W; Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S
Cancer Sci; 2016 Jul; 107(7):1013-7. PubMed ID: 27089226
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the outcomes of metastatic papillary renal cell carcinoma.
Connor Wells J; Donskov F; Fraccon AP; Pasini F; Bjarnason GA; Beuselinck B; Knox JJ; Rha SY; Agarwal N; Bowman IA; Lee JL; Pal SK; Srinivas S; Scott Ernst D; Vaishampayan UN; Wood LA; Simpson R; De Velasco G; Choueiri TK; Heng DYC
Cancer Med; 2017 May; 6(5):902-909. PubMed ID: 28414866
[TBL] [Abstract][Full Text] [Related]
3. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Passalacqua R; Buzio C; Buti S; Porta C; Labianca R; Pezzuolo D; Camisa R; Sabbatini R; Benecchi L; Messina C; Cengarle R; Vaglio A; Dalla Chiesa M; Tomasello G; Caminiti C
Cancer Immunol Immunother; 2010 Apr; 59(4):553-61. PubMed ID: 19779715
[TBL] [Abstract][Full Text] [Related]
4. Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).
Seidel C; Busch J; Weikert S; Steffens S; Bokemeyer C; Grünwald V
Br J Cancer; 2013 Dec; 109(12):2998-3004. PubMed ID: 24169357
[TBL] [Abstract][Full Text] [Related]
5. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
[TBL] [Abstract][Full Text] [Related]
6. YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α.
Takeuchi A; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Dejima T; Tanaka S; Itsumi M; Eto M; Naito S
Cancer Immunol Immunother; 2013 Mar; 62(3):517-27. PubMed ID: 23052245
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The JEWEL study.
Ohba K; Monji K; Osawa T; Yamana K; Yasuda Y; Tanaka H; Nakagawa Y; Fukuyama T; Matsubara N; Uemura H; Sakai H; Eto M
Int J Urol; 2023 Nov; 30(11):977-984. PubMed ID: 37434386
[TBL] [Abstract][Full Text] [Related]
8. Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients.
Dielmann A; Letsch A; Nonnenmacher A; Miller K; Keilholz U; Busse A
Cancer Immunol Immunother; 2016 Feb; 65(2):181-92. PubMed ID: 26753694
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.
Peters I; Dubrowinskaja N; Abbas M; Seidel C; Kogosov M; Scherer R; Gebauer K; Merseburger AS; Kuczyk MA; Grünwald V; Serth J
PLoS One; 2014; 9(3):e91440. PubMed ID: 24633192
[TBL] [Abstract][Full Text] [Related]
10. What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?
Diekstra MH; Liu X; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Jan; 18(1):1-4. PubMed ID: 27967336
[No Abstract] [Full Text] [Related]
11. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
[TBL] [Abstract][Full Text] [Related]
12. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study.
Beisland C; Johannesen TB; Klepp O; Axcrona U; Torgersen KM; Kowalski J; Solli O; Sandin R; Oldenburg J
Onco Targets Ther; 2017; 10():371-385. PubMed ID: 28144152
[TBL] [Abstract][Full Text] [Related]
13. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.
Spees LP; Dinan MA; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George DJ; Scales CD; Pritchard JE; Leapman M; Gross CP; Wheeler SB
Clin Genitourin Cancer; 2022 Oct; 20(5):e396-e405. PubMed ID: 35595633
[TBL] [Abstract][Full Text] [Related]
14. Optimizing clinical benefit with targeted treatment in mRCC: "Tumor growth rate" as an alternative clinical endpoint.
Milella M
Crit Rev Oncol Hematol; 2016 Jun; 102():73-81. PubMed ID: 27129438
[TBL] [Abstract][Full Text] [Related]
15. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.
Bjoern J; Juul Nitschke N; Zeeberg Iversen T; Schmidt H; Fode K; Svane IM
Oncoimmunology; 2016 Apr; 5(4):e1100788. PubMed ID: 27141381
[No Abstract] [Full Text] [Related]
16. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
[TBL] [Abstract][Full Text] [Related]
17. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
[TBL] [Abstract][Full Text] [Related]
18. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
Koster BD; Santegoets SJAM; Harting J; Baars A; van Ham SM; Scheper RJ; Hooijberg E; de Gruijl TD; van den Eertwegh AJM
Cancer Immunol Immunother; 2019 Jun; 68(6):1025-1035. PubMed ID: 30852622
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study.
Schultze-Seemann W; Schulz H; Tschechne B; Häckl M
Anticancer Res; 2019 Feb; 39(2):875-882. PubMed ID: 30711970
[TBL] [Abstract][Full Text] [Related]
20. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.
Tarhini AA; Lee SJ; Li X; Rao UNM; Nagarajan A; Albertini MR; Mitchell JW; Wong SJ; Taylor MA; Laudi N; Truong PV; Conry RM; Kirkwood JM
Clin Cancer Res; 2019 Jan; 25(2):524-532. PubMed ID: 30420448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
